Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease----Data Presented at the 2025 Muscular ...

Wearable and implantable biosensors that can accurately detect biological molecules in a non- or minimally invasive manner ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics ...

Although numerous compounds that target individual or multiple cells or pathways have demonstrated antifibrotic potential, the reality is that only a small number of candidates have progressed ...

Correspondence to Professor Jonel Trebicka, European Foundation for the Study of Chronic Liver Failure, Travessera de Gràcia, 11, 7th floor, Barcelona 08021, Spain; jonel.trebicka{at}efclif.com The ...

Multiple sclerosis (MS) is a chronic disease that involves demyelination of plaque throughout the white and gray matter of the central nervous system. The early stages of MS are usually marked by a ...

announces the filing of a new patent application directed to the use of Thykamine™ as an antifibrotic agent. Backed by in vivo data, the patent application displays the potential effectiveness ...

announces the filing of a new patent application directed to the use of Thykamine™ as an antifibrotic agent. Backed by in vivo data, the patent application displays the potential effectiveness of ...

Backed by in vivo data, the patent application displays the potential effectiveness of thylakoid extracts in treating and slowing the progression of fibrosis, and in down regulating several genes ...

As the only industry-led forum providing biopharma with the insights necessary to make strategic and scientific decisions on their fibrosis pipeline, the 6th Antifibrotic Drug Development Summit ...

The purpose of this review is to provide an overview of emerging antifibrotic agents that have shown encouraging results in preclinical or early clinical studies, but have not yet been approved for ...